Mifepristone: clinical pharmacology

A Robbins, IM Spitz - Clinical obstetrics and gynecology, 1996 - journals.lww.com
Many processes in female reproductive physiology depend on progesterone. This hormone
facilitates the action of estradiol in inducing the luteinizing hormone (LH) surge in the …

Clinical applications of mifepristone

OS Tang, PC Ho - Gynecological endocrinology, 2006 - Taylor & Francis
Mifepristone is a progesterone antagonist that has been studied for a number of clinical
applications. It is a well-known abortifacient that is effective for both first-and second …

Mifepristone: current knowledge and emerging prospects.

AS Kakade, YS Kulkarni - Journal of the Indian Medical Association, 2014 - europepmc.org
The first clinically available antiprogestin, mifepristone has generated immense interest in
the research community since its' discovery in 1980. Mifepristone is a synthetic orally active …

Pharmacological properties of mifepristone: toxicology and safety in animal and human studies

R Sitruk-Ware, IM Spitz - Contraception, 2003 - Elsevier
Roussel Uclaf in partnership with the INSERM unit of Prof. EE Baulieu first discovered
mifepristone (RU486) as part of a large research program on steroidal compounds with …

[HTML][HTML] Clinical utility of mifepristone: apprising the expanding horizons

ZV Karena, H Shah, H Vaghela, K Chauhan, PK Desai… - Cureus, 2022 - ncbi.nlm.nih.gov
Mifepristone is a progesterone and glucocorticoid receptor antagonist. Medical abortion with
mifepristone and prostaglandin has revolutionized the abortion process extending abortion …

Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology

A Im, LJ Appleman - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: Mifepristone is a synthetic selective progesterone-receptor modulator
(SPRM) that is widely used around the globe in the field of reproductive medicine. At present …

Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties

Y Sun, M Fang, H Davies, Z Hu - Gynecological Endocrinology, 2014 - Taylor & Francis
Nowadays, unwanted pregnancy is a major globe tragedy for millions of women, associated
with significant direct and indirect costs, no matter for individuals or society. The …

Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

RN Brogden, KL Goa, D Faulds - Drugs, 1993 - Springer
Synopsis Mifepristone is a potent oral antiprogestogen which acts at the level of the
receptor, having a high affinity for the progesterone receptor. Most of the clinical trials have …

Approval of mifepristone (RU 486) in Europe.

R Sitruk-Ware - Zentralblatt fur Gynakologie, 2000 - europepmc.org
The discovery of mifepristone (ex-RU486) was the achievement of a large research
programme on steroidal compounds with antihormone properties conducted at Roussel …

[PDF][PDF] Progesterone receptor antagonists

IM Spitz - Current Opinion in Investigational Drugs, 2006 - researchgate.net
Since the discovery of the progesterone receptor antagonist mifepristone, numerous
additional compounds, which display a spectrum of biological actions ranging from full …